Advertisement
Singapore markets close in 22 minutes

  • Straits Times Index

    3,410.11
    -29.77 (-0.87%)
     

  • Nikkei

    40,912.37
    -1.28 (-0.00%)
     

  • Hang Seng

    17,799.61
    -228.67 (-1.27%)
     

  • FTSE 100

    8,259.41
    +18.15 (+0.22%)
     

  • Bitcoin USD

    54,341.00
    -3,601.97 (-6.22%)
     

  • CMC Crypto 200

    1,125.96
    -82.74 (-6.84%)
     

  • S&P 500

    5,537.02
    +28.01 (+0.51%)
     

  • Dow

    39,308.00
    -23.90 (-0.06%)
     

  • Nasdaq

    18,188.30
    +159.54 (+0.88%)
     

  • Gold

    2,375.10
    +5.70 (+0.24%)
     

  • Crude Oil

    84.13
    +0.25 (+0.30%)
     

  • 10-Yr Bond

    4.3550
    0.0000 (0.00%)
     

  • FTSE Bursa Malaysia

    1,609.01
    -7.74 (-0.48%)
     

  • Jakarta Composite Index

    7,227.08
    +6.19 (+0.09%)
     

  • PSE Index

    6,492.75
    -14.74 (-0.23%)
     

Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

Vandana Singh
·2-min read
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?
Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday?

On Monday, EyePoint Pharmaceuticals Inc. (NASDAQ:EYPT) announced the topline results of its Phase 2 PAVIA trial evaluating Duravyu (vorolanib intravitreal insert), previously known as EYP-1901, in patients with non-proliferative diabetic retinopathy (NPDR).

The data demonstrated that Duravyu has a biologic effect in patients with NPDR and a favorable safety and tolerability profile; however, the trial did not meet the pre-specified primary endpoint.

The company plans to provide an update on the path forward for Duravyu as a potential treatment in NPDR following a review of the full 12-month data.

ADVERTISEMENT

PAVIA topline interim results include:

  • 86% of patients in the 3mg arm and 80% of patients in the 2mg arm demonstrated stable or improved disease at nine months versus 70% in the control arm.

  • 0% of patients in the 3mg arm and 5% of patients in the 2mg arm worsened ≥2-step at nine months vs. 10% in the control arm.

  • 5% of patients in the 3mg arm and 0% of patients in the 2mg arm achieved a ≥2-step improvement in DRSS score at nine months versus 5% in the control arm.

  • Continued favorable safety and tolerability profile with no Duravyu-related ocular or systemic serious adverse events reported. No cases of endophthalmitis or retinal vasculitis (occlusive or non-occlusive) were observed.

The company remains on track to reach additional clinical milestones with Duravyu, with the initiation of the first Phase 3 pivotal trial in wet AMD, LUGANO, anticipated in the second half of 2024, the second global Phase 3 pivotal trial in wet age-related macular degeneration, LUCIA, to follow, and the readout of topline data from the Phase 2 VERONA trial in diabetic macular edema anticipated in the first quarter of 2025.

Read Next: Why Is Age-Related Blindness Focused EyePoint Pharmaceuticals Stock Trading Over 300% Today?

Price Action: EYPT shares are down 29.9% at $13.84 during the premarket session at last check Monday.

"ACTIVE INVESTORS' SECRET WEAPON" Supercharge Your Stock Market Game with the #1 "news & everything else" trading tool: Benzinga Pro - Click here to start Your 14-Day Trial Now!

Get the latest stock analysis from Benzinga?

This article Why Is EyePoint Pharmaceuticals Stock Plummeting On Monday? originally appeared on Benzinga.com

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.